MedTrace Logo

Alfuzosin Versus Placebo in Acute Urinary Retention

NCT00453908 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2007-08-20

No results posted yet for this study

Summary

The primary objective of the study is to investigate if 14 days of treatment with Alfuzosin compared to placebo, will increase the number of patients with satisfying spontaneous voiding after acute urinary retention treated with Clean Self-Catheterization.

Furthermore is investigated the safety of the medical treatment and self-catheterization.

Conditions

  • Urinary Retention

Interventions

DRUG

Alfuzosin

Sponsors & Collaborators

Principal Investigators

  • Henning Andersen, MD · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31

Countries

  • Denmark

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00453908 on ClinicalTrials.gov